Functional Target Validation for Alzheimer's Disease-Related Dementias
This grant supports research to rigorously validate new therapeutic targets for Alzheimer's Disease-Related Dementias, aiming to accelerate treatment development through phased, milestone-driven projects.
Funder: National Institutes of Health
Due Dates (Anticipated): November 2026 (Full application deadline, projected)
Funding Amounts: $1,800,000 total program funding; ~2 awards expected; phased multi-year projects
Summary: Supports rigorous, milestone-driven functional validation of new therapeutic targets for Alzheimer’s Disease-Related Dementias (ADRD) to accelerate translational research.
Key Information: This opportunity is forecasted; applications are not yet being solicited.
Description
The National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, anticipates supporting ambitious research projects focused on comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease-Related Dementias (ADRD). The initiative aims to overcome a major barrier in ADRD treatment development: the lack of well-validated targets directly linked to disease mechanisms.
Projects will be supported through a phased award mechanism (e.g., R61/R33), starting with the development of technologies, models, and protocols to manipulate candidate targets and assess their physiological consequences in relevant in vitro and in vivo models. Upon achieving predefined milestones and proof-of-concept, projects may advance to a second phase emphasizing cross-validation of target effects across experimental modalities and laboratories, adhering to NIH rigor and reproducibility standards.
The goal is to de-risk translational research and accelerate the development of novel therapeutic strategies for ADRD.
